Results 21 to 30 of about 88,800 (280)

Case selection and outcome of radical perineal prostatectomy in localized prostate cancer

International Brazilian Journal of Urology, 2003
Radical prostatectomy continues to play a central role in the management of localized prostate cancer. The majority of patients diagnosed with prostate cancer will undergo radical prostatectomy.
Jeffrey M Holzbeierlein, Peter Langenstroer, H.J Porter II, J. Brantley Thrasher   +3 more
doaj   +1 more source

Extended pelvic lymph node dissection at the time of robot-assisted radical prostatectomy: Impact of surgical volume on efficacy and complications in a single-surgeon series [PDF]

, 2015
INTRODUCTION: We assessed the impact of surgical volume on perioperative outcomes and complications of robotic extended pelvic lymph node dissection (ePLND).
Danuser, Hansjörg, DI PIERRO, GIOVANNI BATTISTA, GRANDE, PIETRO, Mattei, Agostino, Wirth, Johann Gregory   +4 more
core   +1 more source

Anesthesia for radical prostatectomy

Acta chirurgica Iugoslavica, 2005
Radical prostatectomy is one of most common treatment options currently recommended for clinically localized prostate cancer. Evaluation of intraoperative and postoperative complications is important in evaluation of relative morbidity of this treatment option.
J, Filimonovic, B, Gvozdic, B, Krivic, M, Acimovic, C, Tulic, J, Hadzi Djokic   +5 more
openaire   +3 more sources

Open and robotic radical prostatectomy

Asian Journal of Urology, 2019
Open retropubic radical prostatectomy has been the “gold standard” treatment for locally confined prostate cancer (PCa) but in recent years minimal invasive techniques as laparoscopy and robot-assisted prostatectomy have become widely available.
Hendrik van Poppel, Wouter Everaerts, Lorenzo Tosco, Steven Joniau   +3 more
doaj   +1 more source

Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. [PDF]

, 2017
Purpose Despite documented oncologic benefit, use of postoperative adjuvant radiotherapy (aRT) in patients with prostate cancer is still limited in the United States.
Abdollah, Firas, Briganti, Alberto, Dalela, Deepansh, Davicioni, Elai, Den, Robert B., Dicker, Adam P., Freedland, Stephen J., Karnes, R. Jeffrey, Menon, Mani, Ross, Ashley E., Santiago-Jiménez, María, Schaeffer, Edward M., Yousefi, Kasra   +12 more
core   +2 more sources

Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. [PDF]

, 2017
BackgroundPET/MRI can be used for the detection of disease in biochemical recurrence (BCR) patients imaged with 68Ga-PSMA-11 PET. This study was designed to determine the optimal MRI sequences to localize positive findings on 68Ga-PSMA-11 PET of patients
Behr, Spencer C, Carroll, Peter R, Greene, Kirsten L, Hope, Thomas A, Lake, Spencer T, Small, Eric J, Westphalen, Antonio C, Zagoria, Ronald   +7 more
core   +1 more source

LAPAROSCOPIC RADICAL PROSTATECTOMY

Journal of Urology, 2005
After the pioneering period when only few teams were performing the procedure, the laparoscopic approach to radical prostatectomy has become widespread with several technical variations. A comprehensive review of the published literature on laparoscopic radical prostatectomy was performed to determine the current state of the art of this surgical ...
Edouard J, Trabulsi, Bertrand, Guillonneau   +1 more
openaire   +5 more sources

Salvage robotic radical prostatectomy

Indian Journal of Urology, 2014
Failure of non-surgical primary treatment for localized prostate cancer is a common occurrence, with rates of disease recurrence ranging from 20% to 60%.
Samuel D Kaffenberger, Joseph A Smith
doaj   +1 more source

MRI-targeted or standard biopsy for prostate-cancer diagnosis [PDF]

, 2018
Background Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who ...
Allen, Clare, Bladou, Franck, Borghi, Marcelo, Boxler, Silvan, Brew-Graves, Chris, Briganti, Alberto, Budäus, Lars, Campa, Riccardo, Catalano, Carlo, Crouzet, Sébastien, D'Eramo, Giuseppe, Deeks, Jonathan, Del Monte, Maurizio, Eggener, Scott, Emberton, Mark, Freeman, Alex, Ghei, Maneesh, Giganti, Francesco, Gill, Inderbir, Grompone, Marcello Domenico, Hadaschik, Boris A, Hellawell, Giles, Hindley, Richard G, Jim C, Hu, Kasivisvanathan, Veeru, Klotz, Laurence, Leonardo, Costantino, Margolis, Daniel, Moore, Caroline M, Morris, Stephen, Mynderse, Lance A, Panebianco, Valeria, Pinto, Peter, Precision, Study Group Collaborators, Punwani, Shonit, Rannikko, Antti S, Robert, Grégoire, Roobol, Monique J, Ruffion, Alain, Salvo, Vincenzo, Sciarra, Alessandro, Singh, Paras B, Takwoingi, Yemisi, Taneja, Samir S, Vaarala, Markku H, Venderink, Wulphert, Villeirs, Geert M, Villers, Arnauld, Virdi, Jaspal, Williams, Norman R   +49 more
core   +1 more source

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. [PDF]

, 2014
BackgroundSipuleucel-T is a US Food and Drug Administration-approved immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Its mechanism of action is not fully understood.
Amling, Christopher L, Carroll, Peter, Chan, Stephen, Corman, John, Fong, Lawrence, Frohlich, Mark W, Lewis, Jera, Sheikh, Nadeem A, Simko, Jeffrey, Sims, Robert B, Small, Eric J, Stephenson, Robert A, Weinberg, Vivian   +12 more
core   +2 more sources